Biomarkers associated with checkpoint inhibitors
- PMID: 27122549
- DOI: 10.1093/annonc/mdw181
Biomarkers associated with checkpoint inhibitors
Abstract
Checkpoint inhibitors (CPI), namely anti-CTLA4 and anti-PD1/PD-L1 antibodies, demonstrated efficacy across multiple types of cancer. However, only subgroups of patients respond to these therapies. Additionally, CPI can induce severe immune-related adverse events (irAE). Biomarkers that predict efficacy and toxicity may help define the patients who may benefit the most from these costly and potentially toxic therapies. In this study, we review the main biomarkers that have been associated with the efficacy (pharmacodynamics and clinical benefit) and the toxicity (irAE) of CPIs in patients.
Keywords: biomarkers; cancer; checkpoint inhibitors; immunotherapy.
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Comment in
-
Don't forget the host: a potential role for germinal polymorphisms as markers for checkpoint inhibitors.Ann Oncol. 2017 Feb 1;28(2):435-436. doi: 10.1093/annonc/mdw554. Ann Oncol. 2017. PMID: 28426100 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
